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Abstract
Background: In a previous study, we demonstrated that intravenous administration of adipose tissue stem cells
(ASCs) could significantly reduce allergic symptoms and suppress eosinophilic inflammation.
Methods: To evaluate the secretome of ASCs, we administrated culture supernatant of ASCs (ASC sup, which
contains the ASC secretome) and uncultured fresh medium (con sup) into a mouse model of allergic airway
inflammation. Subsequently we observed the mice for signs of inflammation and investigated Th1-, Th2-, and Treg-
related cytokine levels as well as recruitment of Treg cells into the airway.
Results: We found that ASC sup could ameliorate allergic airway inflammation in this model; the value of airway
hyperresponsiveness, and the occurrence of inflammatory cell infiltration in the lung, as well as the number of
eosinophils, and goblet cells in the lung epithelium were all significantly decreased by ASC sup treatment. In
addition, ASC sup treatment significantly decreased the levels of IL-4, IL-5, and IL-13 in the bronchial alveolar lavage
fluid and in culture medium of lung-draining lymph node cells of the animal model of acute asthma. We detected
numerous CTLA-4 and Foxp3-expressing cells in the lung after ASC sup treatment. ASC sup was found to have a
higher concentration of IL-10 and TGF-β compared to con sup.
Conclusions: Stem cells have powerful potential for therapeutic functions in various diseases, but they also have
many drawbacks. In this study, we found strong immunosuppressive ability of ASC sup in an allergic airway mouse
model. It may be possible to use ASC sup for treatment of many immunological diseases in the near future.
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Background
Mesenchymal stem cells (MSCs) have been isolated from
a variety of tissues, such as skeletal muscle, bone mar-
row, chondrocytes, umbilical cord, bone, and adipose tis-
sue [1]. The expansive abilities of MSCs make them one
of the most important candidates for disease therapy
and regenerative medicine. In addition, they have strong
immunosuppressive activity in different situations, and
clinical trials are ongoing evaluating them for treatment
of immunological disease [2–4]. MSCs could control the
immune function of most immune cells involved in al-
lergen and antigen recognition of antigen-presenting
cells, natural killer cells, T cells, and B cells [2].
MSCs derived from adipose tissue stem cells (ASCs)
may share with other MSCs the ability to suppress inflam-
mation and immune responses [5]. Our research group is
interested in the possibility of using ASCs as therapeutic
agents for allergic airway diseases. We demonstrated that
intravenous administration of ASCs could reduce allergic
symptoms significantly and suppress eosinophilic inflam-
mation [6, 7]. In addition, we found that ASCs signifi-
cantly suppressed the production of Th2-associated
cytokines [interleukin (IL)-4, IL-5, and IL-13], and im-
proved Th1 cytokine [interferon gamma (IFN-γ)] produc-
tion, in a mouse model of allergic airway inflammation. In
addition, CD4+CD25+Foxp3+ T cells (regulatory T cells,
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Treg) and regulatory cytokines [IL-10 and transforming
growth factor-beta (TGF-β)] were significantly increased
in the lung immune system [6, 7]. Moreover, this activa-
tion was inhibited by prostaglandin E2 (PGE2) and TGF-
β-neutralizing antibodies. Because PGE2 and TGE-β play
a role in inducing Treg expansion, the immune suppres-
sion effects of ASCs are closely related with Treg cell re-
cruitment and activation.
Recently, it has been reported that culture supernatant
of MSCs could suppress T cell proliferation in an in vitro
model [8, 9], and that feline mesenchymal stem cell
supernatant could inhibit reactive oxygen species pro-
duction by feline neutrophils [10]. Cruz et al., suggested
that human bone marrow-derived cells extracellular vesi-
cles also ameliorate Aspergillus hyphal extract-induced al-
lergic airway inflammation in immunocompetent mice
[11]. In addition, Ionescu et al., reported that secreting
soluble factors of bone marrow-derived cell prevented air-
way hyperresponsiveness (AHR) and inflammation. In the
chronic asthma model, the soluble factors prevented
airway smooth muscle thickening and peribronchial in-
flammation [12]. The soluble factors upregulated an IL-
10-induced and IL-10-secreting subset of T regulatory
lymphocytes and promoted IL-10 expression by lung
macrophages [12]. However, there are no reports on
whether secreted soluble factors of human ASCs can act
as an anti-inflammatory and immune-regulatory response
under airway inflammation situations like those of bone
marrow-derived cells.
Lee et al. reported the secretion of 187 proteins from
human ASCs activated by tumor necrosis factor-alpha
(TNF-α) [13]. Therefore, we reasoned that ASCs could
secrete many proteins (secretome) including cytokines
and chemokines in an artificial culture system; this
secretome might be a good candidate for immunoregu-
latory therapeutic agents. In this study, we adminis-
trated culture supernatant of ASCs (ASC sup) to a
mouse model of allergic airway inflammation, and ob-
served their signs of airway inflammation. We also in-
vestigated Th1-, Th2-, and Treg-related cytokine levels
and recruitment of Treg cells to the airway. Addition-
ally we studied the expression level of chemokine




Six-week-old female C57BL/6 mice were purchased from
Samtako Co. (Osan, Republic of Korea), and Foxp3-GFP
(expressing GFP-tagged Foxp3) mice were purchased
from the Jackson Laboratory, Bar Harbor, ME, USA.
They were bred in a specific pathogen-free animal facil-
ity during experiments. The animal study protocol was
approved by the Institutional Animal Care and Use
Committee of the Pusan National University (Approval
No. PNU-2016-1109).
Isolation and culture of ASCs
Adipose tissue was obtained from the abdominal fat of
C57BL/6 mice according to previous reports [6, 14].
Briefly, adipose tissue was digested with 0.075% collage-
nase type I (Sigma-Aldrich, St. Louis, MO, USA) at 37 °
C for 30 min after washing with phosphate-buffered sa-
line (PBS). After neutralization, the sample was centri-
fuged at 1200 × g for 10 min. The pellet was incubated
overnight at 37 °C in 5% CO2 in control medium
[α-MEM, 10% fetal bovine serum (FBS), 100 unit/ml
penicillin, 100 μg/ml streptomycin]. Following incuba-
tion, residual non-adherent cells were removed. The at-
tached cells of ASCs (third or fourth passages) were
used in experiments after phenotypic classification of
the ASCs, according to previous methods [6, 14].
ASC sup collection and endotoxin depletion
ASCs, at a concentration of 1 × 105 cells/cm2, were cul-
tured until reaching 1 × 106 cells/cm2 (about 48 hours)
in α-MEM containing 10% FBS at 37 °C in 5% CO2 [6].
After centrifugation (12,000 × g for 30 min), the superna-
tants of ASC culture (ASC sup) and fresh culture
medium control supernatant (con sup) were collected
and concentrated (about 50- fold) by applied pressure
using a concentrator (Amicon, Millipore Corporations,
Billerica, MA, USA) with 3000-Da pore size membranes.
The unnecessary excessive salts were eliminated from
collected supernatants using a HiTrap Desalting™ kit
(GE Healthcare, Uppsala, Sweden). Lipopolysacharide
(LPS) was depleted (endotoxin levels < 0.01 μg/ml) from
the concentrated supernatant using Detoxi-Gel Affinity
Pak prepacked columns (Pierce, Rockford, IL, USA), in
accordance with the manufacturer’s instructions.
Mouse model of allergic airway inflammation
A mouse model of allergic airway inflammation was in-
duced as previously reported with minor modification
[14, 15]. Briefly, mice were sensitized by intraperitoneal
injection of 75 μg of OVA (Sigma-Aldrich, St. Louis,
MO, USA) in 200 μL PBS containing 10 mg/ml
aluminum hydroxide (Sigma-Aldrich) on days 0, 1, 7,
and 8. On days 14, 15, 21, and 22 after the initial
sensitization, the mice were challenged intranasally with
50 μg of OVA in 50 μL PBS (Fig. 1a).
Measurement of airway hyperresponsiveness (AHR)
Twenty-four hours after the last challenge, the AHR was
assessed in conscious, unrestrained mice using noninva-
sive whole-body plethysmography (Allmedicus, Seoul,
Korea) as previously described [15]. In brief, the mice were
placed in the plethysmography chamber and exposed to
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increasing concentrations of aerosolized methacholine at
0, 12.5, 25, and 50 mg/ml for 10 min. The enhanced pause
(PenH) was calculated automatically based on the mean
pressure generated in the plethysmography chamber dur-
ing inspiration and expiration combined with the time of
each phase. The PenH values calculated during each 3-
min interval were then averaged.
Differential cell counting in bronchoalveolar lavage fluid
(BALF)
After sacrificing the animal, the BALF was collected from
mouse lungs as outlined in previous reports [15, 16]. The
BALF samples were centrifuged for 5 min at 500 × g at 4 °
C. The supernatants were collected and immediately fro-
zen at -70 °C. Cell pellets were resuspended and washed
twice in PBS. The total cell numbers were counted using a
hematocytometer. BALF cell smears were prepared using
a cytospin apparatus, and stained with Diff-Quik solution
(Sysmex Co., Kobe, Japan) to determine the differential
cell counts in accordance with conventional morpho-
logical criteria. At least 500 cells per slide were evaluated
in order to obtain the differential leukocyte counts.
Lung histology and inflammation scoring
Lung tissues were removed after lavage, fixed in 10%
neutral formalin for 36 hours, and embedded in paraffin.
Thin sections of embedded tissues were stained with
hematoxylin and eosin (H&E) for identification of eosin-
ophils and periodic acid-Schiff (PAS) for counting
mucin-secreting cells. The lung inflammation score was
assessed by the degree of peribronchial and perivascular
inflammation, which were evaluated on a subjective scale
of 0–4 as previously described [17]. For quantifying gob-
let cell hyperplasia, the percentage of PAS-positive cells
in epithelial areas was examined in eight to ten tissue
sections per mouse.
Measurement of serum immunoglobulins
At 48 hours after the last OVA challenge, serum was
collected from mice via cardiac puncture. Total and
OVA-specific immunoglobulins (IgE, IgG1, IgG2a) were
determined by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions
(R&D Systems, Minneapolis, MN, USA). Absorbance
(450 nm) was measured with an ELISA plate reader
(Molecular Devices, Sunnyvale, CA, USA).
Expression of cytokines in the BALF and lung-draining
lymph nodes
Lung-draining lymph nodes (LLNs) were observed be-
tween the trachea and both lung lobes in the OVA-
induced animal model of acute asthma. Lymphocytes
AHR
Sacrifice
0  1                7   8        12 13  14 15        19 20  21 22   23  24  (days)  
OVA + Alum or PBS OVA
con sup or ASCs sup.
b c
Fig. 1 The adipose-derived stem cell cultured supernatant (ASC sup) reduced OVA-Alum-induced allergic airway inflammation. a Mice were sensitized
on days 0, 1, 7, and 8 by intraperitoneal injection of OVA plus Alum or PBS (control) only. The mice were challenged on days 14, 15, 21, and 22
intranasally with OVA. 10 μg/50 μL of the con sup or ASC sup were injected intranasally on days 12, 13, 19, and 20. b The enhanced pause (PenH) was
evaluated at baseline and after treatment with increasing doses of aerosolized methacholine (0–50 mg/ml). Open triangle; PBS-treated mice [PBS], open
circle; Ova-Alum-treated mice [OVA], solid triangle; control sup-treated mice after Ova-Alum treatment [con sup + OVA], solid square; ASC sup-treated
mice after Ova-Alum treatment [ASC sup + OVA]. b Airway resistance values in response to methacholine (0 to 50 mg/ml) were evaluated. c The
number of inflammatory cells in the BALF samples was counted after Diff-Quik staining. (*p < 0.05, ***p < 0.001, n = 5 mice per group, experiments were
performed in triplicate)
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were isolated from LLNs according to previous reports
[14]. The lymphocytes were plated in 48-well plates
coated with 0.5 μg/ml CD3 antibody (BD Pharmigen™,
BD Biosciences, San Jose, CA, USA) at a concentration
of 106 cells/ml in RPMI 1640 with 10% FBS. Plated cells
were incubated for 72 hours at 37 °C with 5% CO2. After
stimulation, the supernatant was used for experiments.
The concentrations of IL-4, IL-5, IL-10, IL-13, interferon
(IFN)-γ, and TGF-β in the BALF and in supernatants of
LLNs were examined using ELISA kits according to the
manufacturer’s instructions (eBioscience, San Diego, CA,
USA). The absorbance of the final reactant was deter-
mined at 450 nm with an ELISA plate reader.
FACS analysis of T cell distribution in LLN
To evaluate the recruitment of Th1, Th2, and Treg
induced by ASC sup treatment, the LLN cells of the
OVA-induced animal model of acute asthma and ASC
sup-treated animal model of acute asthma were cul-
tured on anti-CD3-coated plates for 6 hours. To deter-
mine the CD4+CD25+Foxp3+ (Treg) and IL-10
+/CD4+ T
cell populations, the cells were stained with anti-CD4-
FITC (0.5 mg/ml) and/or anti-CD25-APC (0.2 mg/ml)
in accordance with the manufacturer’s recommenda-
tions (eBioscience, San Diego, CA, USA). After surface
staining, the cells were permeabilized using a Cytofix/
Cytoperm kit (eBioscience). After permeabilization, the
cells were stained with anti-Foxp3-PE-cy7 or anti-IL-
10-PE (eBioscience). To quantify the Th1 and Th2 cell
populations, the LLN cells were stained with an anti-
CD4-FITC antibody. After surface staining, the CD4+ T
cells were stained with intracellular anti-IFN-γ-PE-cy7
(eBioscience) and anti-IL-4-PE (eBioscience) antibodies.
Fluorescence was measured using a FACS CantoII cyt-
ometer (BD Biosciences) equipped with Canto software
(BD Biosciences).
Determination of Treg cell recruitment in the lung
To test Treg cell recruitment to the lung after ASC sup
treatment, allergic airway inflammation was induced in
Foxp3-GFP mice treated with ASC sup or control sup.
After induction, five mice per group were sacrificed and
lung tissues were embedded in paraffin. Some sections
were stained with an anti-CTLA-4 antibody (activation
marker of Treg) as previously reported [15]. The Alexa
Fluor 594 goat anti-hamster IgG secondary antibody
(1∶500; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) was applied to the slide for 1 hour at
24 °C. The slides were washed in PBS and incubated
with DAPI for 2 min. Confocal images of stained lung
tissue or stained Treg cells were examined under an
inverted fluorescence microscope.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
western blot
To identify the molecular weights of proteins in the
supernatant samples, SDS-PAGE was performed using
ASC sup and control sup, according to the manufac-
turer’s instruction Bio-Rad Laboratories, Hercules, CA,
USA). The electrophoresed gels were transferred to
Hybond-C extra nitrocellulose membranes (Amersham
Biosciences, Little Chalfont, UK) as performed in a pre-
vious study [18]. TGF-β in the ASC sup was measured
using an anti-TGF-β antibody (10 μg/g body weight in
200 μL PBS; R&D Systems, Minneapolis, MN, USA).
Statistical analysis
All experiments were repeated a minimum of three
times. Data are expressed as mean ± SEM. Statistical sig-
nificance was assessed by the Student’s t test using the
SPSS software package version 18.0 (SPSS Inc., Chicago,
IL, USA). A value of p < 0.05 was considered significant.
Results
Treatment with ASC sup suppressed OVA-induced airway
inflammation
To demonstrate the effects of ASC sup on OVA-induced
airway inflammation, we pretreated the airways of an
OVA-induced mouse model with ASC sup (at 10 μg/50
μl), and assessed biological and pathological changes
(Fig. 1a). The value of AHR to methacholine was in-
creased in OVA-induced mice. However, when treating
with ASC sup, AHR was significantly diminished
(Fig. 1b). In addition, control sup treatment also de-
creased the AHR value; however, the AHR values of con-
trol sup-treated mice were significantly higher than
those of ASC sup-treated mice. Inflammatory cell infil-
tration was also observed in the airways after OVA-
induced allergic inflammation. The numbers of eosino-
phils were especially increased after OVA induction of
allergic airway inflammation. However, when mice were
treated with ASC sup, eosinophil numbers significantly
decreased in the airway (Fig. 1c). Histological examin-
ation of the lungs, after OVA-induced airway inflamma-
tion, exposed massive inflammatory cell infiltration,
bronchial epithelial cell hyperplasia, and goblet cell
hyperplasia (Fig. 2a). However, treatment with ASC sup
remarkably decreased infiltration of inflammatory cells,
goblet cell hyperplasia, and mucin production (Fig. 2a).
Furthermore, after OVA treatment, the number of in-
flammatory cells was significantly lower around the peri-
vascular and peribronchiolar regions of ASC sup-treated
mice than control mice (Fig. 2b). In addition, the per-
centage of PAS-positive cells in the epithelial area of
OVA-treated mice was up to 80%; however, only 30%
PAS-positive cells were observed in the epithelia of the
ASC sup-treated group (Fig. 2c).
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ASC sup treatment reduced OVA–induced Th2 response
in the BALF and LLN
BALF and LLN lymphocytes from OVA-induced mice
showed significantly increased levels of IL-4, IL-5, and
IL-13 in the culture media of these cells (Fig. 3a and b).
However, ASC sup treatment of the animal model of
acute asthma in this model significantly decreased these
high levels of IL-4, IL-5, and IL-13 (Fig. 3a and b). In
contrast, ASC sup treatment significantly increased IL-
10 and TGF-β in both samples from the animal model
of acute asthma (Fig. 3a and b). Similar results were ob-
tained from FACS analysis of LLN cells. IL-4-secreting
CD4+ T cells were significantly decreased, but IFN-γ-
secreting CD4+ T cells were considerably increased in
the ASC sup-treated group compared to the OVA or
OVA control sup group. The population of CD4+CD25
+Foxp3+ T cells and IL-10-secreting CD4+ T cells were
obviously increased by administration of ASC sup treat-
ment in the animal model of acute asthma compared to
those of the control sup-treated asthmatic group (Fig. 4).
Also mean fluorescence intensity (MFI) of CD4+CD25
+Foxp3+ markers were considerably increased in the
ASC sup-treated group compared to the OVA or OVA
control sup group (Additional file 1: Figure S1). Further-
more, total and OVA-specific IgE and IgG1 levels were
significantly higher in the OVA group than in the PBS-
H&E PAS
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Fig. 2 Treatment with ASC sup decreased inflammatory cell infiltration and mucus production. a Tissue inflammation observed in stained lung
sections (a, e: PBS-treated mice [PBS]; b, f: OVA-Alum-induced airway inflammation mice [OVA]; c, g: OVA-Alum-induced airway inflammation mice
with con sup treatment [con sup + OVA]; d, h: OVA-Alum-induced airway inflammation mice with ASC sup treatment [ASC sup + OVA]; a-d:
H&E-stained; e-h: PAS-stained (bar = 100 μm). b Portions of hematoxylin-and eosin-stained inflated lung sections were blindly examined under
light microscopy to assess the inflammation score of each section. We determined the inflammation score, which is the product of the severity
and prevalence of inflammation, performed by as previous desribed [17]. Severity was assigned a numerical value based on the thickness of the
inflammatory cell infiltrates surrounding the airways and blood vessels in the lung (0 = no cells; 1 = 1 − 3 cells thick; 2 = 4 − 6 cells thick; 3 = 7 − 9 cells
thick; 4 = greater than or equal to 10 cells thick). Prevalence was assigned a numerical value, according to the percentage of airways and blood vessels in
each section encompassed by inflammatory cells (0 = no airways or blood vessels; 1 = <25%; 2 = 25 − 50%; 3 = 51− 75%; 4 = >75%). c The percentage of
PAS-positive cells in epithelial areas was examined from eight to ten tissue sections per mouse. Each value is expressed as the mean ± SD. (**p< 0.01,
***p < 0.001, n = 5 mice per group, experiments were performed in triplicate)
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treated group; however, intranasal pretreatment of ASC
sup significantly decreased total IgE and OVA-specific
IgE in the animal model of acute asthma (Fig. 5).
Foxp3+ cells infiltrate the airway around sites of
inflammation
To evaluate Treg cell migration to lung, we also induced
allergic airway inflammation (using OVA) in Foxp3-
eGFP mice after pretreatment with control sup and ASC
sup as above. GFP-expressing Foxp3 cells were observed
using confocal microscopy. After induction of allergic
airway inflammation, some Foxp3-expressing cells were
found in the lung matrix, and most of them did not ex-
press CTLA-4 (Fig. 6a and b). However, numerous
CTLA-4 expressing Foxp3-eGFP cells were detected in
the lung after ASC sup treatment (Fig. 6d and e).
CTLA-4 and Foxp3 expression was higher in the ASC
sup treatment group compared to that of the control
sup treatment group; almost all Foxp3-eGFP cells in the
lungs of ASC sup-treated mice strongly expressed
CTLA-4, a surface marker for Treg-cell activation
(Fig. 6c-e).
IL-10 and TGF-β were highly expressed in ASC sup
To identify the proteins present in control sup and
ASC sup, each sample was analyzed using SDS-PAGE.
Various proteins (3–100 kDa and heavier) were ob-
served in both samples, but extra protein bands were
identified in ASC sup (Additional file 2: Figure S2).
Proteins of approximately, 150 kDa, 80 kDa, and 50
kDa, as well as several proteins below 26 kDa were
additionally observed in ASC sup. To determine if
these small additional proteins were IL-10 and/or
TGF-β, we compared IL-10 and TGF-β levels in con-
trol sup and ASC sup using ELISA. Levels of both of
these Treg cell-related cytokines were significantly
higher in ASC sup than in control sup (Fig. 7a). In
addition, high levels of TGF-β in ASC sup were
a b LLNBALF
Fig. 3 Treating with ASC sup regulated cytokine expression levels in OVA-induced BALF and LLNs. Cytokine concentrations in BALF(a) and in the
culture medium of CD3-stimulated lymphocytes isolated from LLNs(b). For activation of lymphocytes from LLN, the wells were incubated with 1
μg/ml of anti-CD3 antibody for 16 hours at 4 °C. The lymphocytes (4 × 105 cells per well) were introduced to the well and incubated for 3 days.
After activation, the levels of several cytokines were measured in the supernatant using ELISA kits; ELISA assays were conducted in accordance
with the manufacturer’s instructions. (PBS; BALF or culture supernatant of LLN from PBS-treated mice, OVA; BALF or culture supernatant of LLN
from OVA-Alum-induced airway inflammation mice, con sup + OVA; BALF or culture supernatant of LLN from OVA-Alum-induced airway inflamma-
tion mice with con sup treatment, ASC sup + OVA; BALF or culture supernatant of LLN from OVA-Alum-induced airway inflammation mice with
ASC sup treatment. *p < 0.05, **p < 0.01, ***p < 0.001, n = 5 mice per group, experiments were performed in triplicate)
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Fig. 4 Regulation of T cell subsets by treatment with ASC sup. The lymphocytes from LLNs were cultured with stimulated anti-CD3 antibody. Each
1 × 106 lymphocytes per sample were analyzed after surface and internal staining with various antibodies. After gating with CD4+ T cells (a), IL-4+,
IFN-γ+, IL-10+, CD25+, and Foxp3+, T cells were counted by FACS analysis (b). (OVA lymphocytes from LLN of OVA-Alum-induced airway inflammation
mice, con sup + OVA lymphocytes from LLN of OVA-Alum-induced airway inflammation mice with con sup treatment, ASC sup + OVA lymphocytes from
LLN of OVA-Alum-induced airway inflammation mice with ASC sup treatment. n = 5 mice per group, experiments were performed in triplicate)
Fig. 5 ASC sup treatment decreases total and OVA-specific IgE and IgG1 expression. The mice serum was diluted (as indicated) in PBS, for
measurement of OVA-specific IgE (1:40), IgG1 (1: 105), and IgG2a (1:105) levels by ELISA. (PBS; serum from PBS-treated mice, OVA; serum from
OVA-Alum-induced airway inflammation mice, con sup + OVA; serum from OVA-Alum-induced airway inflammation mice with con sup treatment,
ASC; sup + OVA serum from OVA-Alum-induced airway inflammation mice with ASC sup treatment. *p < 0.05, **p < 0.01, ***p < 0.001, n = 5 mice per
group, experiments were performed in triplicate)
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demonstrated by western blot analysis using an anti-
TGF-β monoclonal antibody (Fig. 7b).
Discussion
There are many reports on the ability of stem cells to
suppress allergy and immune responses, but the detailed
mechanisms and core molecules have not been identi-
fied. Although mechanistically unclear, most of the
evidence suggests that Treg cells make important contri-
butions to the suppression of Th2 immune responses
during allergic airway inflammation [6, 14]. Herein, we
demonstrated that the ASC-derived secretome, con-
tained in the culture supernatant, even without ASCs,
could ameliorate allergic airway inflammation through
suppressed Th2 cytokine production and recruitment of
activated Treg cells into the airway.
Lin et al. observed that after transplantation of bone
marrow-derived MSCs into the stomach of mice with an
H. pylori infection, migration of MSC cells, from the
subserosal to the mucosal layer of the stomach, was de-
tected at 28 days posttransplantation [19]. The MSCs
significantly stimulated systemic and local IL-10-
secreting T cells and Treg cells [19]. Nemeth et al. dem-
onstrated that bone marrow-derived MSCs suppressed
allergic responses in a mouse model of ragweed-induced
asthma, and elicited the recruitment of Treg cells to the
lung and enhanced the concentration of TGF-β in serum
and in BALF [20]. However, these effects were









Fig. 6 Recruitment of Treg cells into the lung after ASC sup treatment. Paraffin sections of lungs from Foxp3-eGFP mice (green) were stained by
immunofluorescence for CTLA-4 (red), and nuclei (DAPI, blue) representative pictures are shown, (white bar = 100 μm). (a) PBS lung of PBS-treated
mice, (b) OVA lung of OVA-Alum-induced airway inflammation mice, (c) con sup + OVA lung of OVA-Alum-induced airway inflammation mice with
con sup treatment, (d) ASC sup + OVA lung of OVA-Alum-induced airway inflammation mice with ASC sup treatment, Merge; merge of CTLA-4,
GFP, and DAPI fields, Mag-Merge; magnification of Merge, Arrowhead; indicated CTLA4+Foxp3+ T cells. (e) Average ratio of CTLA4+Foxp3+ cells
among total cells in the lung of each group was analyzed using the Image J program. (The value was calculated by three different authors who
analyzed ten random spots of each slides). n = 5 mice per group, experiments were performed in triplicate
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suppressed by TGF-β inhibitor treatment. Cahill et al.
demonstrated that protection mediated by MSCs was
associated with activated Treg in the lung and increas-
ing IL-10 production in allergic airway inflammation
[21]. In previous studies, we also found increased Treg
cell and IL-10-secreting T cells recruitment after ASC
adaptive transfer, and the immunosuppressive ability of
ASCs was closely related to prostaglandin E2 and TGF-
β production [6, 14].
Although there are many reports about the immuno-
modulation effects of MSCs, we found only a few
reports about the immunosuppressive effects of culture
supernatant and core molecules from MSCs. Culture
supernatant of human neural stem cells (HB1.F3) has a
therapeutic effect on acute stroke and intracerebral
hemorrhage, and suppresses the proliferation of human
peripheral T cells, including the CD3 + CD103+ subpop-
ulation [8]. After treating T cells with culture super-
natant from human neural stem cells, the secretion of
IL-2 was significantly decreased, whereas that of IL-4,
IL-10, TNF-α, and IFN-γ was increased. In this study,
we found amelioration of asthma signs in an OVA-
Alum-induced mouse model of allergic airway inflam-
mation through ASC culture supernatant treatment
(Figs. 1 and 2). This was associated with a decrease in
Th2 cytokine (IL-4, IL-5, and IL-13) production in lung
and peripheral lymph node cells and an increase in IL-
10 and TGF-β levels (Fig. 3). Th2 cytokine-secreting T
cells in LLN were also decreased by ASC sup treatment
(Fig. 4). In addition, Treg cell recruitment in ACS sup
treatment group was also observed (Fig. 6). Therefore,
ASC sup probably has immunosuppressive ability similar
to ASCs.
Lee at al. investigated the secretome of human adipose
tissue-derived mesenchymal stem cells (hASCs) using li-
quid chromatography coupled with tandem mass spec-
trometry [13]. They identified about 200 individual
proteins in hASC-conditioned media; among them, 118
proteins were secreted at higher levels. The secretome in-
cluded a variety of cytokines and chemokines such as IL-
6, IL-8, CXCL6, and monocyte chemotactic protein-1
(MCP-1). Their results were quite different from our re-
sults; IL-6, IL-8, and MCP-1 are closely associated with
movement of monocytes, whereas IL-10, TGF-β, Indolea-
mine 2,3-dioxygenase (IDO), and PGE2 are related to Treg
cell activation. To obtain high concentrations of cytokines
and chemokines, they stimulated hASCs with TNF-α, a
well-known mediator of inflammation. Thus, they only
identified pro-inflammation-related cytokines and chemo-
kines from stem cells; this might be quite different to what
is occurring in a normal culture situation or in vivo. In
our study, ASC sup was obtained without any stimulation,
and we detected enhanced concentrations of IL-10 and
TGF-β after cultivation of ASCs (Fig. 7).
IL-10, which is referred to as the cytokine synthesis in-
hibitory factor, is an anti-inflammatory cytokine that is
capable of inhibiting pro-inflammatory cytokine synthe-
sis. IL-10 is generated primarily by Treg cells, and has
been shown to induce Treg cell differentiation [22, 23].
There are many reports about IL-10 expression by vari-
ous MSCs during various situations [24–27]. Yang et al.
also demonstrated that splenocytes stimulated with allo-
antigen in the presence of MSC culture supernatant pro-
duced a significant amount of IL-10, which was










Fig. 7 Protein analysis of con sup and ASC sup. a IL-10 and TGF-β
expression level in ASC sup and con sup were measured by ELISA.
b Both concentrated culture medium. 30 μg was loaded and the
proteins were separated using SDS-PAGE. The proteins were transferred
onto a nitrocellulose membrane and incubated with antibody specific
for TGF-β. (***p < 0.001, experiments were performed in triplicate)
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secreting cells, confirmed by an ELISPOT assay [26].
They suggested that because MSCs could not suppress T
cell proliferation under IL-10 blockade, MSC secreting
IL-10 plays a major role in the suppression of T cell pro-
liferation [26]. TGF-β has also been implicated in the
conversion of naive CD4+CD25- T cells into CD4+CD25+
T cells via the activity of Foxp3. TGF-β also promotes
the in vivo expansion and suppressive function of CD4
+CD25+ Treg cells [28, 29]. In stem cells, TGF-β is one of
the most important molecules for their regeneration and
differentiation ability [30, 31]. To repair wounds or tis-
sue, stem cells must receive extrinsic signals from their
surrounding environment, and integrate them with in-
trinsic abilities, to self-renew and differentiate to ultim-
ately produce tissues. The TGF-β superfamily constitutes
integral components for the crosstalk between stem cells
and their microenvironment [32]. Elevated production of
IL-10 and TGF-β in vitro and in vivo in our model led
us to propose that Treg cells were involved in the ameli-
oration of the inflammatory response induced by ASC
sup. In addition, CTLA-4-expressing Treg cells were sig-
nificantly recruited through ASC sup treatment. CTLA-
4 can be found on activated Treg cells, which was shown
to activate the transmission of immunosuppressive sig-
nals on T effector cells by interacting the T effector li-
gands CD80 and CD86 [33, 34]. To find other
immunomodulatory molecules in ASC sup, we also tried
two-dimensional analysis of ASC sup without any stimu-
lation. However, we did not obtain conclusive results
(data not shown). In the ASC culture medium, 10% FBS
was present. FBS is essential for in vitro cultivation of
ASCs, and contains many seroproteins (Fig. 7). To get
ASC-specific proteins, the concentration of FBS in
medium would have to be reduced to a minimum level
(below 1%). However, in these conditions, ASCs could
not survive.
The ability of stem cells to differentiate is their most
powerful function from a therapeutic standpoint; however,
they also have the ability to differentiate into cancer cell
lines. In addition, stem cells have many limitations in
therapeutic use; as of now, only the patient’s own stem
cells can be used for therapy, as the immunological rejec-
tion response needs to be avoided. Presently, a method for
developing stem cells suitable for a patient’s situation has
not been reported. Before clinical trials are initiated, much
more needs to be known about how to control stem cell
proliferation, and differentiation into specific phenotypes,
induce their integration into existing neural and synaptic
circuits, and optimize functional recovery in animal
models closely resembling the human disease [35].
Conclusions
In this study, we found strong immune suppressive ef-
fects of culture supernatant from ASCs in an allergic
airway mouse model. This supernatant has many advan-
tages, including safety, ease of handling, ability to be
stored for long periods, and usage in patients. Although
we need more information about ASC sup before use in
therapy, this strategy could be used to treat many im-
munological diseases in the near future.
Additional files
Additional file 1: Figure S1. Mean fluorescence intensity (MFI) of CD4
+CD25+Foxp3+ T cell in LLN of ASC sup-treated and airway inflammation-
induced mice. MFI value of CD4+CD25+Foxp3+ markers in LLN of ASC
sup-treated and asthma-induced mice have significantly higher value
than those of asthma-induced mice (**, p < 0.001). (PPT 131 kb)
Additional file 2: Figure S2. SDS-PAGE of supernatant after ASC
cultivation. Comparison of protein composition of con sup (concentrated
medium for ASCs cultivation) and ASC sup (concentrated culture
supernatant after ASC cultivation for 3 days) using SDS-PAGE. Thirty
micrograms of each sample was loaded into an SDS-PAGE gel. After
electrophoresis, the gel was stained by Coomassie Blue (M molecular
marker, arrow indicated extra proteins compared to control). (PPT 370 kb)
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